Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial

Table 2 Summary of treatments

Items		TOCE	TOCE + HAIC	Provability 95%CI
Items		n = 9	n = 10	Provability 95%CI
Number of Treatment Session	(1/2/3/4/5/6/7/8)	6/1/1/1/0/0/0/0	3/1/1/1/2/1/0/1	0.057
	Total	15	36
	Median	1	3.5
	Range	1–4	1–8
Interval between Sessions (day)	Median	94.5	90.5	0.96
Interval between Sessions (day)	Range	56–259	48–518	0.96
DDP-H (mg/body)	Median	N/A	80	N/A
DDP-H (mg/body)	Range	N/A	40–100	N/A
Miriplatin (mg/body)	Median	62	62	0.99
Miriplatin (mg/body)	Range	40–120	16–120	0.99
anti-tumor Effect^a	CR	0 (0)	6 (3)	0.0025
	PR	0 (0)	7 (2)
	SD	6 (3)	15 (5)
	PD	9 (9)	8 (8)
	Not evaluable	0	0
	DCR (%)	40.0	77.8
Disease Progression (day)	Median	91	423	0.025
Disease Progression (day)	Range	29–322	34–1243	1.17–10.86
Overall Survival (day)	Median	706	733	0.40
Overall Survival (day)	Range	62–1176	384–1827	0.54–4.54

^a anti-tumor effect was evaluated based on the modified Response Evaluation Criteria In Solid Tumors guideline. CR complete response, PR partial response, SD stable disease, PD progressive disease, DCR disease control rate, HR hazard ratio, TOCE transarterial oily chemoembolization, TACE transarterial chemoembolization, HAIC hepatic arterial infusion chemotherapy

ISSN: 1471-2407